Boston-based Neurable, which builds an OS for brain-computer interfaces, raised a $35M Series A led by Spectrum Moonshot Fund, bringing its total raised to $65M
Neurable, a neurotechnology company, raised a $35 million Series A round led by the Spectrum Moonshot Fund, CEO Ramses Alcaide tells Axios Pro exclusively.
Context & Ripple Effects
Neurable’s round adds a software-platform entrant to a brain-computer-interface funding stream that has also backed device developers. Precision Neuroscience’s $102M Series C and Inbrain’s $50M round show investors financing multiple approaches to the category.
The new funding follows larger private rounds at Neuralink, including its $280M Series D, while Neurable is positioning around an OS rather than a single implant or imaging device. That distinction makes the company’s ability to attract developer, device-maker, and user adoption central to the value of the round.
First-order effects
- Neurable gains $35M in new capital and reaches $65M raised, giving it additional resources to develop and commercialize its brain-computer-interface OS.
- Spectrum Moonshot Fund becomes the lead investor in a platform-layer BCI company, tying its investment to Neurable’s ability to establish that OS as a usable interface across the emerging ecosystem.
Second-order effects
- Device-focused BCI companies such as Precision and Neuralink may face stronger pressure to clarify whether their products will support third-party software layers or retain vertically integrated stacks.
- The round makes software interoperability a more visible competitive question for BCI developers: hardware companies could become prospective partners, customers, or rivals if Neurable’s OS gains traction.
Third-order effects
- If BCI funding continues to span implants, imaging hardware, and operating systems, the market could segment into specialized layers rather than converge on a single fully integrated winner.
- Capital may increasingly favor teams that can connect technical BCI advances to repeatable software distribution, though adoption and compatibility—not fundraising alone—will determine whether a platform layer emerges.
The trend: Brain-computer-interface investment is broadening from financing individual devices toward financing the software layers that could coordinate a multi-vendor neurotechnology market.